Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Gerardo Caruso and Maria Caffo
Affiliation: Neurosurgical Clinic, Department of Neuroscience, A.O.U. Policlinico “G. Martino”, via Consolare Valeria, 1, 98125 Messina, Italy.
Gliomas are the most common and malignant primary brain tumors in the adult population. Despite the intensive
research on cancer pathology, real mechanisms concerning glioma progression are not completely understood. The
prognosis in patients affected by malignant gliomas is still very unfavorable. Recent genomic analyses have revealed patterns
of molecular changes within tumor subclasses that harbor distinct underlying biology, clinical prognosis, and pathogenic
routes. So, novel treatments will have to be able to interfere at different molecular levels in gliomagenesis minimizing
the toxicity. In particular, antisense oligonucleotides are able to inhibit expression of specific genes by interfering with
transcription or, more usually, with translation.
In this review, we will focus on mechanisms of antisense oligonucleotides reporting clinical and experimental studies. We
will also report a large number of patents which adopt the antisense oligonucleotides as potential therapeutic approach in
Keywords: Angiogenesis, antisense oligonucleotides, apoptosis, gliomas.
Rights & PermissionsPrintExport